Track market-moving stories before they get noisy

Intapp, Inc. (NASDAQ: INTA - Get Free Report) has been assigned an average rating of "Hold" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company. The

Intapp (INTA) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.26 per share a year ago.

Intapp, Inc. (INTA) Q3 2026 Earnings Call Transcript

PALO ALTO, Calif.--(BUSINESS WIRE)--Chicago-based investment bank Republic Partners adopts Intapp DealCloud to standardize sell-side operations, unify deal and relationship management.

-

Latest release adds AI work code prediction and one-click narrative compliance, plus more of the timekeeping flexibility professional services firms need to protect earned revenue and drive firmwide adoption.

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp (NASDAQ: INTA), the governed AI platform for professional firms in highly regulated industries, today announced the latest release of Intapp Time. The release introduces new AI capabilities and timekeeping experiences that make it even easier to capture every hour of work — AI work code prediction, configurable narrative tone and style enforcement, a new timeline view, and mobile timekeeping enhancements.

Intapp Time makes every engagement more profitable by capturing every hour worked, protecting revenue already earned, and generating insights to help firms continuously improve performance. Already trusted by the world’s leading professional services firms, Intapp Time provides engagement intelligence and revenue governance, helping drive $12 billion in incremental billings each year.

“Intapp Time helps the world's leading firms operate more profitably, with total compliance and maximum flexibility for every professional,” said Ken Houseman, Vice President and General Manager of Time at Intapp. “Now we're accelerating our AI roadmap to eliminate the moments where revenue leaks: the wrong code, the non-compliant narrative, the entry that never got recorded.”

Revenue leakage rarely occurs all at once. It happens in the moments between work and time capture — when entries are delayed, coded inconsistently, or returned during billing review due to incomplete narratives. Building on the reengineered web and mobile experiences released in August 2025 and February 2026, the new Intapp Time release applies AI directly within a firm’s existing time entry workflow to accurately capture more time faster.

“Our clients told us the most powerful place to apply AI is inside the workflow their people already use, not next to it,” explained Houseman. “That's what this release delivers. Capturing every hour worked and protecting earned revenue is the foundation, not the ceiling.”

What’s new

Our latest Intapp Time release offers several new capabilities:

AI work code prediction: Protect revenue by eliminating the coding errors that result in downstream billing issues and write-downs. AI knows when phase, task, and activity codes are required and adds them based on the narrative and matter coding history weighted by recency. Rather than manually look up, enter, and second-guess every entry, timekeepers can simply review and accept them. Configurable narrative tone and style enforcement: Effortlessly deliver consistent, scalable compliance with firm and client requirements. Administrators configure rules covering outside counsel guidelines, restricted terms, and block billing. AI then validates every narrative and recommends rewrites that timekeepers can accept with a single click at the point of time entry. Timeline view: Eliminate revenue leakage caused by underreported or lost time. Intapp Time’s new chronological view lays out time entries throughout the workday alongside AI-captured activity. Timekeepers can then map activities to the gaps in their day, turning them into complete time entries with just a few clicks. Mobile timekeeping enhancements: Capture work in the moments it’s most likely to be lost. On-the-go timekeepers can now start, stop, and switch timers in the Intapp mobile app using Siri voice commands, run timers in the background, and automatically sync offline activity when connectivity is restored. Today’s release is another step in Intapp Time’s accelerating cadence of AI innovation, with each enhancement building on the last to help make every engagement more profitable. This summer, Intapp will share what’s next — including agentic AI workflows embedded in Intapp Time that further automate critical firm processes, reduce friction in day-to-day work, surface more engagement intelligence, and drive profitable compliant growth.

Availability

The latest capabilities in this release of Intapp Time are available now on Intapp Cloud Infrastructure. Learn more or request a demo at intapp.com/time-tracking, or contact your Intapp account team.

About Intapp

Intapp (NASDAQ: INTA) is the governed AI platform for professional firms in highly regulated industries. Intapp’s vertically tailored agentic solutions are built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, law, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Learn why the world’s top firms trust Intapp’s industry-specific enterprise solutions at intapp.com.

More News From Intapp, Inc.

Back to Newsroom

-

The Nordic strategy and management consultancy will use Intapp DealCloud to unify pipeline management, strengthen client relationships, and drive firm growth

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp (NASDAQ: INTA), the governed AI platform for professional firms in highly regulated industries, today announced that Arkwright Consulting has chosen Intapp DealCloud as its deal and relationship management solution. The Nordic strategy and management consultancy will use DealCloud to centralize contact and relationship data, manage its project pipeline, improve reporting across its partner group, and drive firm growth.

Leading change

Arkwright Consulting advises corporate leaders on strategic decisions, including growth strategy, M&A, and business transformation. It also supports financial investors with commercial M&A work, principally commercial due diligence and other transaction-related strategic advice. The firm's partners work across a broad network of relationships spanning corporate clients, private equity investors, and portfolio companies throughout the Nordics and beyond.

Prior to selecting DealCloud, Arkwright's partners managed client relationships, business development, and project pipeline across a combination of spreadsheets and email — an approach that limited visibility into the firm's collective network and made consistent reporting across the partner group difficult. As Arkwright continues to formalize and evolve its processes, the firm needed a platform it could adapt quickly without the cost and complexity of custom development. DealCloud's ease of configuration was a decisive factor in the selection process.

Arkwright's partners also recognized a natural alignment with DealCloud through existing relationships, as several of the firm's private equity clients in the Nordics are already DealCloud users. This gives Arkwright direct familiarity with the platform and creates a more connected workflow for commercial due diligence and other transaction work with the investors it supports.

Addressing deal and relationship management

“DealCloud will give our partners a single place to manage our relationships, track our pipeline, and make better decisions about where to focus our business development efforts,” said Kristoffer Birkeland, Principal at Arkwright Consulting. “For a firm like ours, where partners are at the center of every client relationship, having that visibility and structure in one place is a significant step forward.”

For a consulting firm where relationships are the business, collective intelligence is a competitive advantage. DealCloud gives Arkwright's professionals a shared foundation by consolidating relationship data, project and pipeline activity, and business development in one place. Partners can now coordinate more effectively, forecast more accurately, and spend less time chasing information and more time building the relationships that matter.

Multiplying success with Intapp

“Arkwright Consulting represents exactly the kind of firm we built DealCloud to serve — strategy advisors who need purpose-built tools that match how they actually work,” said Tom Koehler, Global Managing Principal of Accounting and Consulting Industries at Intapp. “We're pleased to expand our presence in the Nordics with a leading strategy and management consultancy, and we look forward to supporting Arkwright as it grows.”

This engagement reflects Intapp's continued momentum with consulting firms and extends the company's growing footprint across the EMEA region. Arkwright joins a broader set of strategy and advisory firms turning to DealCloud to replace ad hoc, spreadsheet-based processes with a scalable, industry-specific platform built for the way professional advisors manage relationships and pursue new business.

A partnership rooted in excellence

Arkwright's DealCloud deployment is being delivered in partnership with Frend Digital, a Nordic-based consulting and technology partner. Frend brings deep regional expertise to the engagement and is managing the implementation, data migration, and continued expansion of the platform.

The firm will deploy DealCloud using the advisory industry blueprint, which is preconfigured for consulting firms and includes out-of-the-box capabilities for pipeline and forecasting, execution and process management, and reporting. The blueprint also includes a custom quoting tool configuration to support Arkwright’s proposal pricing workflows.

About Intapp

Intapp (NASDAQ: INTA) is the governed AI platform for professional firms in highly regulated industries. Intapp's vertically tailored agentic solutions are built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, law, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Learn why the world's top firms trust Intapp's industry-specific enterprise solutions at intapp.com.

About Arkwright Consulting

Arkwright is an international management consultancy with Nordic roots, offering strategy and advisory services to private corporations, investors, NGOs, and startup companies from offices in Oslo, Stockholm, Hamburg, and London. Founded in 1987, the firm has built decade-long industry expertise across the sectors that anchor the Nordic economy — including energy, both oil services and renewables, as well as maritime, process and industrial, retail, and IT and high-tech — and works closely with private equity clients on investment opportunities across all industries. Arkwright helps clients develop and implement value-creating strategies in areas spanning corporate and business unit strategy, M&A and commercial due diligence, transformation, and innovation. For more information, visit arkwright.com.

More News From Intapp, Inc.

Back to Newsroom

PALO ALTO, Calif.--(BUSINESS WIRE)--Global law firm Ropes & Gray selects Intapp DealCloud with Celeste to strengthen relationship management and bring agentic AI across the practice.

-

Newly launched restructuring-focused investment bank selects Intapp DealCloud to track relationships, manage deal pipeline, and scale with confidence

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp (NASDAQ: INTA), the governed AI platform for professional firms in highly regulated industries, announces that Ensis Partners, a growing investment bank, has selected Intapp DealCloud with Celeste to build its relationship and deal management foundation for its growing investment bank.

Building for the future

Ensis Partners is a New York City–based investment bank specializing in restructuring and bankruptcy advisory — a highly specialized segment of the investment banking landscape. Founded by seasoned industry veterans Richard Shinder and Mark Buschmann — who collectively bring decades of experience from firms including PJT Partners, Perella Weinberg, Blackstone, and Citigroup — Ensis launched in February 2026 with a clear vision: to create a firm purpose-built for the restructuring vertical.

From the outset, the firm’s founders recognized the importance of establishing a strong technology foundation before deals began to flow in earnest. Ensis Partners moved quickly to implement a platform capable of scaling with the firm, rather than waiting until data quality became a challenge.

As both founders had direct prior experience with DealCloud, including evaluating and deploying it at previous firms, Shinder and Buschmann didn’t need to evaluate competing CRM platforms. DealCloud's track record within their professional networks made it the clear choice.

"We knew from experience what good relationship and deal management infrastructure looks like, and we knew DealCloud was the right platform to build on,” said Shinder. “Starting with clean, structured data from day one means we're setting ourselves up for success as we grow, rather than trying to fix problems down the line."

Addressing relationship intelligence and deal management

Setting a foundation with AI in mind was a priority for the firm’s founders. Celeste, Intapp's agentic AI platform for financial and professional firms, is native to DealCloud — giving Ensis a single platform that structures its founders’ deep relationship networks and turns them into a competitive asset.

Ensis will use DealCloud to navigate the firm's restructuring business with full visibility into their relationship ecosystem, deal pipeline, associated fees and structures, and the complex constituent dynamics that define restructuring engagements. With AI that understands the firm's deal and relationship context, professionals can put that intelligence to work through natural conversation — surfacing insights on demand, automatically extracting key details from engagement documents, and keeping data current without manual data entry.

Partnering for success

To facilitate a smooth deployment of DealCloud, Ensis is working with Monarch, an Intapp partner that helps firms implement and derive long-term value from DealCloud. Monarch will leverage its proven implementation playbook and hands-on deployment approach to drive high-quality outcomes and long-term success for Ensis Partners' investment professionals.

"We're thrilled to be partnering with Ensis Partners at such an exciting stage of its journey,” said Brian Bissonette, Industry Principal, Investment Banking at Intapp. “The firm's founders bring exceptional experience and relationships in the restructuring space, and we look forward to helping them build an intelligent, scalable foundation — one that turns their relationships and deal activity into a real competitive advantage as the firm grows."

About Ensis Partners

Ensis Partners is a boutique, New York City–based investment banking and restructuring advisory firm founded by Richard Shinder and Mark Buschmann. The firm provides comprehensive restructuring and liability management advice relevant to complex capital structures and financial situations. With a focus on the upper-middle market, Ensis offers senior-level expertise across a range of transaction formats, including LMEs, special situations financings, Chapter 11 proceedings, and cross-border engagements. For more information, visit ensispartners.com.

About Intapp

Intapp (NASDAQ: INTA) is the governed AI platform for professional firms in highly regulated industries. Intapp's vertically tailored agentic solutions are built for the specialized workflows, complex relationship networks, and professional compliance requirements of accounting, consulting, investment banking, law, private capital, and real assets firms. By applying Firm AI to core processes and data, Intapp helps partners, dealmakers, and advisors drive firm growth, manage compliance, and improve profitability. Learn why the world's top firms trust Intapp's industry-specific enterprise solutions at intapp.com.

More News From Intapp, Inc.

Back to Newsroom

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Announces Offering of Senior Notes.

Defender Capital LLC. acquired a new stake in ESAB Corporation (NYSE: ESAB) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 35,593 shares of the company's stock, valued at approximately $3,977,000. ESAB accounts for approximately 1.3% of Defender Capital LLC.'s holdings,

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Announces CFO Transition.

Esab (ESAB - Free Report) shares rallied 8.8% in the last trading session to close at $102.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 12.2% loss over the past four weeks.

ESAB Corporation recently announced the appointment of R. Brent Jones as Chief Financial Officer, effective early May 2026. The company also expressed confidence in achieving the lower end of its core organic sales growth outlook, with multiple avenues to reach the upper end despite ongoing geopolitical uncertainty. 

ESAB also reaffirmed its previously issued 2026 guidance of core revenue between $2.85 billion and $2.95 billion, core adjusted EBITDA of $575 million to $595 million, and core adjusted EPS at $5.70-$5.90.

Shares of ESAB gained supported by a broader market rally following a U.S.-Iran ceasefire that eased industrial risk concerns. Expectations of post-war rebuilding and investment in the Middle East are seen as potential tailwinds for ESAB, which has a manufacturing presence in the region.

This maker of welding and cutting equipment is expected to post quarterly earnings of $1.37 per share in its upcoming report, which represents a year-over-year change of +9.6%. Revenues are expected to be $715.3 million, up 10.6% from the year-ago quarter.

While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.

For Esab, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ESAB going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Esab is part of the Zacks Metal Products - Procurement and Fabrication industry. TriMas (TRS - Free Report) , another stock in the same industry, closed the last trading session 4.8% higher at $37.91. TRS has returned -5.1% in the past month.

TriMas' consensus EPS estimate for the upcoming report has changed -21.5% over the past month to $0.18. Compared to the company's year-ago EPS, this represents a change of -60.9%. TriMas currently boasts a Zacks Rank of #5 (Strong Sell).

The Zacks Metal Products - Procurement and Fabrication industry's prospects look bleak in the near term but ESAB and CENX seem poised to tide the challenges.

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB1Q2026--ESAB Corporation Announces First Quarter 2026 Results.

ESAB Corporation (ESAB) Q1 2026 Earnings Call Transcript

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 324

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Completes Acquisition of Eddyfi Technologies.

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that it has entered into a definitive agreement to acquire Onyx-Fire Protection Services Inc. (“Onyx-Fire”), an inspection-first provider of fire and life safety services in Canada, from funds managed by Blackstone Tactical Opportunities (“Blackstone”). The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions, including receipt of re.

APi (APG - Free Report) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +5.26%. A quarter ago, it was expected that this company would post earnings of $0.4 per share when it actually produced earnings of $0.44, delivering a surprise of +10%.

Over the last four quarters, the company has surpassed consensus EPS estimates four times.

APi, which belongs to the Zacks Business - Services industry, posted revenues of $1.98 billion for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 3.56%. This compares to year-ago revenues of $1.72 billion. The company has topped consensus revenue estimates four times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

APi shares have added about 27.2% since the beginning of the year versus the S&P 500's gain of 4.2%.

What's Next for APi?While APi has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for APi was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $0.44 on $2.16 billion in revenues for the coming quarter and $1.67 on $8.51 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Business - Services is currently in the bottom 37% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Willdan Group (WLDN - Free Report) , another stock in the same industry, has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This energy efficiency and sustainability consultant is expected to post quarterly earnings of $0.81 per share in its upcoming report, which represents a year-over-year change of +28.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Willdan Group's revenues are expected to be $89.55 million, up 4.9% from the year-ago quarter.

APi Group Corporation (APG) Q1 2026 Earnings Call Transcript

-

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) ("APi" or the "Company") today announced the pricing of the previously announced private offering by APi Group DE, Inc. ("APi DE"), a wholly owned subsidiary of the Company, of $500 million in aggregate principal amount of 5.75% senior notes due 2034 (the "Notes") at an offering price of 100% of the principal amount thereof. The Notes will be senior unsecured obligations of APi DE and will be fully and unconditionally guaranteed on a senior unsecured basis by the Company and certain of the Company's existing and future foreign and domestic subsidiaries. The offering is expected to close on or before May 14, 2026, subject to the satisfaction of customary closing conditions. APi intends to use the net proceeds from this financing for funding of the recently signed and announced Onyx-Fire Protection Services Inc. and Wtech Fire Group acquisitions, as well as for general corporate purposes.

The Notes are being offered in a private offering solely to parties reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"), and to non-U.S. persons in accordance with Regulation S under the Securities Act. No assurance can be given that the offering of the Notes will be completed, or, if completed, as to the terms on which it will be completed. This release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Forward Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements, and any such forward-looking statements are qualified in their entirety by reference to the following cautionary statements. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements.

About APi:

APi is a global, market-leading business services provider of fire and life safety, security, elevator and escalator, and specialty services with a substantial recurring revenue base and over 500 locations worldwide. APi provides statutorily mandated and other contracted services to a strong base of long-standing customers across industries. APi has a winning leadership culture driven by entrepreneurial business leaders delivering innovative solutions for customers. More information can be found at www.apigroupinc.com.

More News From APi Group Corporation

Back to Newsroom

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”) today announced that its senior leadership team will be participating in a fireside chat during the William Blair 46th Annual Growth Stock Conference on Wednesday, June 3rd at 10:40 a.m. CT. A live webcast link and archived replay will be available in the “Events” area on the Investor Relations page of APi's website at APi Group Investor Relations - Events. Interested parties should check the Compan.

ROCKVILLE, Md. and SUZHOU, China, May 31, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, today announced that the Company presented its first dataset of alrizomadlin (APG-115), an MDM2-p53 inhibitor from the Company’s apoptosis-targeted pipeline, as monotherapy or in combination with lisaftoclax (APG-2575) in pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs), in a rapid oral presentation at the 62nd American Society of Clinical Oncology (ASCO) Annual Meeting.

The ASCO Annual Meeting showcases cutting-edge research in clinical oncology and advanced cancer therapies and is the world’s largest gathering of the clinical oncology community. This year marks Ascentage Pharma’s ninth consecutive appearance at ASCO. A total of six studies involving three of the Company’s key assets were selected for presentation, including three rapid oral presentations.

The data presented demonstrated preliminary antitumor activity and a manageable tolerability profile of alrizomadlin in pediatric solid tumors. Results showed that alrizomadlin monotherapy demonstrated initial clinical benefit in pediatric rhabdomyosarcoma (RMS), with one pediatric patient achieving a complete response (CR). In combination with investigational selective Bcl-2 inhibitor lisaftoclax, encouraging antitumor activity was observed, with an objective response rate (ORR) of 23.5% among 17 response-evaluable patients, including one complete response in a patient with Ewing sarcoma and three partial responses (PRs). In terms of safety, alrizomadlin, either as monotherapy or in combination with lisaftoclax, demonstrated a manageable safety profile in pediatric patients with solid tumors.

Alrizomadlin is an orally administered, highly selective MDM2-p53 inhibitor independently developed by Ascentage Pharma. It is the first investigational agent of its class to enter clinical development in China and has global first-in-class potential. By blocking the MDM2-p53 protein-protein interaction, alrizomadlin restores the tumor suppressor activity of p53 and induces apoptosis in tumor cells. Recently, alrizomadlin was officially included by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) in the Pilot Program for the Support of Anti-tumor Drugs R&D for Kids, also known as the “SPARK Plan,” for development in pediatric solid tumors including neuroblastoma, rhabdomyosarcoma, and Ewing sarcoma.

Professor Yizhuo Zhang, principal investigator of the study from the Department of Pediatric Oncology at Sun Yat-sen University Cancer Center, said: “Relapsed/refractory pediatric sarcomas are associated with extremely poor prognosis and substantial unmet medical needs. The data presented at the ASCO meeting demonstrated a favorable tolerability profile and promising anti-tumor effect for alrizomadlin both as monotherapy and in combination with lisaftoclax, with the complete response (CR) cases being particularly encouraging. As a key candidate included in the SPARK Plan, alrizomadlin has the potential to become a first-in-class therapy, address unmet medical needs, and bring new hope for long-term survival to pediatric patients.”

Professor Yi Zhang, investigator of the study from the Department of Pediatrics at Beijing Tongren Hospital, Capital Medical University, said: “Treatment options for pediatric solid tumors, especially advanced soft-tissue sarcomas, remain very limited. The clinical data generated by the alrizomadlin combination regimen are therefore particularly meaningful. This apoptosis pathway-targeting therapy demonstrated favorable tolerability and encouraging objective response rates, further supporting the therapeutic potential of dual-target combination approaches in refractory pediatric tumors and providing valuable direction for future precision drug development in pediatric oncology.”

Yifan Zhai, MD, Chief Medical Officer of Ascentage Pharma, said: “Pediatric solid tumors continue to represent an area of significant unmet medical need. The data presented at ASCO mark our first presentation of alrizomadlin clinical data in pediatric solid tumor patients and demonstrated encouraging preliminary clinical benefit and tolerability. Importantly, alrizomadlin has already been included by the CDE in the SPARK Plan for potential development in multiple pediatric solid tumors. The data presented provide initial clinical evidence supporting this development strategy. We will continue to advance the related clinical studies with the goal of bringing new treatment options to pediatric patients in urgent need.”

Key highlights from the study presented at the 2026 ASCO Annual Meeting are as follows:

Alrizomadlin (APG-115) alone or in combination with Lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs)
Abstract #: 10012
Presentation Type: Rapid Oral Presentation
Session Title: Pediatric Oncology II
First Author: Yizhuo Zhang, MD, Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine
Key Highlights:

Research Background: This multicenter clinical trial conducted in China evaluated the safety and preliminary efficacy of alrizomadlin (APG-115) as monotherapy or in combination with lisaftoclax in heavily pretreated pediatric patients with relapsed/metastatic RMS, Ewing sarcoma (EWS), neuroblastoma (NB), and other solid tumors.Efficacy Data: In the monotherapy arm, 1 patient with refractory RMS achieved CR. In the combination arm, among 17 response-evaluable pediatric patients with relapsed/refractory solid tumors, the ORR was 23.5%, including 1 CR in a patient with EWS, as well as PRs in 2 patients with RMS and 1 patient with NB. The disease control rate (DCR) was 70.6%.Safety Data: No dose-limiting toxicities (DLTs) were observed in either the monotherapy or combination arm. Adverse events were primarily gastrointestinal and hematologic, with few serious adverse events and no treatment-related deaths or discontinuations.Conclusion: The regimen demonstrated a manageable safety profile and preliminary antitumor activity in pediatric solid tumors, supporting further investigation. * Alrizomadlin is currently under investigation and has not yet been approved by the US FDA.

About Ascentage Pharma

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”) is a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer. The Company has built a rich pipeline of innovative drug products and candidates that include inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.

The Company’s first approved product, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). Ascentage Pharma is currently conducting an FDA- and EMA-cleared registrational Phase III trial, called POLARIS-2, of olverembatinib for CML, as well as an FDA- and EMA-cleared registrational Phase III trials for patients with newly diagnosed Ph+ ALL, called POLARIS-1, and SDH-deficient GIST patients, called POLARIS-3.

The Company’s second approved product, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. Lisaftoclax has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors. The Company is currently conducting four global registrational Phase III trials: the FDA- and EMA- cleared GLORA study of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response; the GLORA-2 study in patients with newly diagnosed CLL/SLL; the GLORA-3 study in newly diagnosed, elderly and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 study in patients with newly diagnosed higher risk MDS.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma’s filings with the SEC, including those set forth in the sections titled “Risk factors” and “Cautionary note regarding forward-looking statements” in its Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-looking Statements” and “Risks Factors” in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited where the Company’s ordinary shares are listed it has made or it makes from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company’s management.

As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma’s current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information
Investor Relations:
Stella Yang
Ascentage Pharma
[email protected] 
+1 (301) 792-6286

Stephanie Carrington
ICR Healthcare
[email protected]
+1 (646) 277-1282

Media Relations:
Sean Leous
ICR Healthcare
[email protected]
+1 (646) 866-4012

APi Group Corporation (APG) Presents at 46th Annual William Blair Growth Stock Conference Transcript

APi Group Corporation (NYSE: APG) (“APi” or the “Company”), a global, market-leading business services provider of safety and specialty services, today